91425-31-9

Usage

General Description

2,5-Pyrrolidinedione, 1-[[[(triphenylmethyl)thio]acetyl]oxy]- is a chemical compound with the molecular formula C28H23NO3S. This medication is a thioester of tripelennamine. It is used as a reducing agent and as a radical initiator in polymer synthesis. 2,5-Pyrrolidinedione, 1-[[[(triphenylmethyl)thio]acetyl]oxy]- is also used in the treatment of various medical conditions, such as to reduce inflammation and pain, and in the management of certain skin conditions. It may also be used as an antioxidant and as a preservative in certain cosmetic and personal care products.

Upstream product

• 6066-82-6 1-hydroxy-pyrrolidine-2,5-dione 
• 34914-36-8 2-(triphenylmethylthio)ethanoic acid 
• 76-83-5 trityl chloride 
• 76-84-6 triphenylmethyl alcohol 

Downstream Products

• 198065-30-4 N-[(tritylmercapto)acetyl]glycylglycylglycine 
• 696606-54-9 N-(2-methoxyphenyl)-2-[(triphenylmethylthio)methylcarbonylamino]ethanamide 
• 696606-81-2 N-[2-aminophenyl]-2-[(triphenylmethylthio)methylcarbonylamino]ethanamide 
• 501327-52-2 N-(2-hydroxyphenyl)-2-[(triphenylmethylthio)methylcarbonylamino]ethanamide 
• 696606-74-3 N-[2-(N-methylamino)phenyl]-2-[(triphenylmethylthio)methylcarbonylamino]ethanamide 
• 492464-46-7 N-[[(triphenylmethyl)thio]acetyl]-L-valine 
• 91425-32-0 2-[(triphenylmethylthio)methylcarbonylamino]ethanoic acid 
• 877474-63-0 N-[[(triphenylmethyl)thio]acetyl]-L-alanine 
• 1345965-27-6 C₃₃H₃₁N₇O₂S 
• 1345965-28-7 C₄₀H₃₇N₇O₂S 
• 1345965-29-8 C₃₆H₃₇N₇O₂S 
• 224184-31-0 methyl DL-2,3-bis[((triphenylmethyl)thio)-acetamido]propionate 

Relevant academic research and scientific papers

Novel mTOR inhibitor compounds and the use thereof

The novel mTOR inhibitor compounds of the present invention are capable of selective drug delivery to bone and released slowly in bone for a long period of time. The present invention relates to a targeted compound linked to a mTOR inhibitory bone disease therapeutic agent.

Novel mTOR inhibitor compounds and the use thereof

The novel mTOR inhibitor compounds of the present invention are capable of selective drug delivery to bone and released slowly in bone for a long period of time. The present invention relates to a targeted compound linked to a mTOR inhibitory bone disease therapeutic agent.

Novel [99mTcN]2+ labeled EGFR inhibitors as potential radiotracers for single photon emission computed tomography (SPECT) tumor imaging

The epidermal growth factor receptor (EGFR) is overexpressed in many cancers, including breast, ovarian, endometrial and non-small cell lung cancer. An EGFR-specific imaging agent could facilitate clinical evaluation of primary tumors or metastases. To achieve this goal, 4-(2-aminoethylamino)-6,7- dimethoxyquinazoline (ADMQ) was synthesized based on a 4-aminoquinazoline core and then conjugated with N-mercapto-acetylglycine (MAG) and N- mercaptoacetyltriglycine (MAG3), respectively, to give compounds 1 and 2. The final complexes [99mTcN]-1 and [99mTcN]-2 were successfully obtained with radiochemical purities of >99% and >98% as measured by radio-HPLC. No decomposition of the two complexes at room temperature was observed over a period of 2 h. Their partition coefficients indicated they were hydrophilic and the electrophoresis results showed they were negatively charged. Biodistribution in tumor-bearing mice demonstrated that the two new complexes showed tumor accumulation, high tumor-tomuscle (T/M) ratios and fast clearance from blood and muscle. Between the two compounds, the 99mTcN-MAG3-ADMQ ([99mTcN]-2) showed the better characteristics, with the tumor/muscle and tumor/blood ratios reached 2.11 and 1.90 at 60 min post-injection, 4.20 and 1.10 at 120 min post-injection, suggesting it could be a promising radiotracer for SPECT tumor imaging.

Preparation and bioevaluation of 99mTc nitrido radiopharmaceuticals with pyrazolo[1,5-a]pyrimidine as tumor imaging agents

The 7-(2-aminoethylamino)-5-methyl-3-cyanopyrazolo[ 1,5-a]pyrimidine (AMCPP) was synthesized and conjugated with N-mercaptoacetylglycine (MAG), N-mercaptoacetylphenylalanine (MAF), and N-mercaptoacetylvaline (MAA), respectively. These three compounds were labeled successfully with [ 99mTcN]2+ intermediate in high radiochemical purities. Biodistribution in tumor-bearing mice demonstrated that the three new complexes showed high tumor-to-muscle (T/M) ratios and rapid clearance from the blood, muscle, liver, kidney, and lung. Among them, the 99mTcN-MAG-AMCPP showed the most favorable characteristics. The tumor/blood and tumor/muscle ratios reached 1.50 and 1.15 at 30 min post-injection, 2.20 and 1.83 at 60 min post-injection. Springer Science+Business Media, LLC 2011.

Synthesis and biological evaluation of pyrazolo[1,5-a]-pyrimidine- containing 99mTc nitrido radiopharmaceuticals as imaging agents for tumors

The compound 5-((2-aminoethylamino)methyl)-7-(4-bromoanilino)-3- cyanopyrazolo[ 1,5-a]pyrimidine (ABCPP) was synthesized and conjugated with N-mercaptoacetylglycine (MAG), N-mercaptoacetylphenylalanine (MAF) and N-mercaptoacetylvaline (MAA), respectively. These three compounds were labeled successfully with [99mTcN]2+ intermediate in high radiochemical purities. Biodistribution in tumor-bearing mice demonstrated that the three new complexes showed tumor accumulation, high tumor-tomuscle (T/M) ratios and fast clearance from blood and muscle. Among them, the 99mTcNMAG-ABCPP showed the most favorable characteristics, with tumor/blood and tumor/muscle ratios reaching 1.51 and 2.97 at 30 min post-injection, 1.84 and 2.49 at 60 min post-injection, suggesting it could be further studied as potential tumor imaging agent for single photon emission computed tomography (SPECT).

Synthesis and biological evaluation of technetium-99m-labeled deoxyglucose derivatives as imaging agents for tumor

Three deoxyglucose (DG) derivatives, S-DG, MAG3-DG and MAMA-BA-DG, were synthesized and labeled successfully with high labeling yields and high radio-chemical purities. Biodistribution in tumor-bearing mice demonstrated that these three new su

Synthesis, biodistribution and qsar studies of five Tc-99M labeled novel N3S pseudo-peptide complexes

Five novel N3S pseudo-peptide chelators derived from mercaptoacetic acid have been synthesized and characterized based on the spectroscopic data. All the chelators were labeled with Technicium-99m to evaluate their biological activities. Invest

Design and synthesis of a novel family of semi-rigid ligands: Versatile compounds for the preparation of 99mTc radiopharmaceuticals

Synthetic pathways to a range of novel semi-rigid tetradentate ligands, with sulfur, amido or amino donor groups, designed to coordinate technetium 99m have been developed. The technetium-99m complexes have been prepared and their stabilities in serum and

Synthesis and characterization of novel N3S chelators and biodistribution of their 99Tcm labeled complexes as potential kidney imaging agents

Two new target chelators were synthesized through five steps with mercaptoacetic acid as the primary material, and identified by spectroscopy data including IR, 1HNMR, 13CNMR, Ms as new kidney imaging agents. The chelators were label

Synthesis of novel N3S pseudo-peptide and biodistribution of 99Tcm-pseudo-peptide complexes in mice

An excellent reaction condition of active ester with amine acid was developed, and a series of novel N3S pseudo-peptide chelators starting from mercaptoacetic acid were synthesized and characterized based on the spectroscopic data, such as IR,